AbbVie, EvolveImmune Therapeutics Strike Deal to Develop Biotherapeutics for Resistant Cancer Cells

Posted on by admin

The deal is expected to leverage EvolveImmune’s T-cell engager EVOLVE platform to develop novel antibody-based therapies for solid and hematologic malignancies.

Leave a Reply

Your email address will not be published. Required fields are marked *